PharmNovo and the School of Pharmacy and Biomedical Sciences at Liverpool John Moores University are collaborating to produce novel nasally delivered small peptide antagonists of the calcitonin gene related peptide (CGRP) receptor for the treatment of migraine. The team has been boosted with the engagement of a new PhD student
In order to provide advice on the clinical potential for PharmNovo’s delta opioid receptor agonists, Professor Andrew Rice from Imperial College London has agreed to become a consultant to the team. Prof Rice is an internationally regarded clinical and scientific expert in the field of chronic pain.
In November, PharmNovo AB opened a new office at the Medicon Village in Lund, Sweden. This science research park is a transformation of former Astra Zeneca buildings now housing over 100 high tec organizations. The location provides extensive opportunities for collaborations at every level of drug development from molecular design
A paper entitled “PN6047, a G protein-biased delta opioid receptor agonist with an improved therapeutic profile for use in chronic pain” was delivered at the Christmas meeting of the British Pharmacological Society at London’s QE2 Centre (17-20th Dec). The communication was given by Dr Alex Conibear who is working in
PharmNovo AB have been granted a patent in the USA for our candidate delta opioid receptor agonist PN6047. This is a key step towards clinical testing for the treatment of chronic pain states. The European Patent Office is very likely to follow suit early in 2019. PN6047 is a biased
New investment is needed to drive PN6047’s progress towards human trials and we have, over the past few months, had additional financial input from a number of private and industrial investors. We now seek larger scale investment and/or a partnership with Pharma to facilitate this development.